217 related articles for article (PubMed ID: 36031632)
1. Impaired insight in schizophrenia: impact on patient-reported and physician-reported outcome measures in a randomized controlled trial.
Lysaker PH; Weiden PJ; Sun X; O'Sullivan AK; McEvoy JP
BMC Psychiatry; 2022 Aug; 22(1):574. PubMed ID: 36031632
[TBL] [Abstract][Full Text] [Related]
2. Insight and its relationship to clinical outcomes in patients with schizophrenia or schizoaffective disorder receiving long-acting risperidone.
Gharabawi GM; Lasser RA; Bossie CA; Zhu Y; Amador X
Int Clin Psychopharmacol; 2006 Jul; 21(4):233-40. PubMed ID: 16687995
[TBL] [Abstract][Full Text] [Related]
3. Insight and medication adherence in schizophrenia: An analysis of the CATIE trial.
Kim J; Ozzoude M; Nakajima S; Shah P; Caravaggio F; Iwata Y; De Luca V; Graff-Guerrero A; Gerretsen P
Neuropharmacology; 2020 May; 168():107634. PubMed ID: 31077729
[TBL] [Abstract][Full Text] [Related]
4. Determinants of patient-rated and clinician-rated illness severity in schizophrenia.
Fervaha G; Takeuchi H; Agid O; Lee J; Foussias G; Remington G
J Clin Psychiatry; 2015 Jul; 76(7):924-30. PubMed ID: 25562591
[TBL] [Abstract][Full Text] [Related]
5. Insight and subjective measures of quality of life in chronic schizophrenia.
Siu CO; Harvey PD; Agid O; Waye M; Brambilla C; Choi WK; Remington G
Schizophr Res Cogn; 2015 Sep; 2(3):127-132. PubMed ID: 26973810
[TBL] [Abstract][Full Text] [Related]
6. Minimum clinically important difference in the Positive and Negative Syndrome Scale with data from the Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE).
Hermes ED; Sokoloff D; Stroup TS; Rosenheck RA
J Clin Psychiatry; 2012 Apr; 73(4):526-32. PubMed ID: 22579152
[TBL] [Abstract][Full Text] [Related]
7. Linking PANSS negative symptom scores with the Clinical Global Impressions Scale: understanding negative symptom scores in schizophrenia.
Leucht S; Barabássy Á; Laszlovszky I; Szatmári B; Acsai K; Szalai E; Harsányi J; Earley W; Németh G
Neuropsychopharmacology; 2019 Aug; 44(9):1589-1596. PubMed ID: 30836381
[TBL] [Abstract][Full Text] [Related]
8. Treatment adherence and insight in schizophrenia.
Bitter I; Fehér L; Tényi T; Czobor P
Psychiatr Hung; 2015; 30(1):18-26. PubMed ID: 25867885
[TBL] [Abstract][Full Text] [Related]
9. [Rationale for the use of long-acting injectable risperidone: a survey of French psychiatrists].
Misdrahi D; Delgado A; Bouju S; Comet D; Chiariny JF
Encephale; 2013 May; 39 Suppl 1():S8-14. PubMed ID: 23541914
[TBL] [Abstract][Full Text] [Related]
10. The relationship between Positive and Negative Syndrome Scale (PANSS) schizophrenia severity scores and risk for hospitalization: an analysis of the CATIE Schizophrenia Trial.
Glick HA; Li P; Harvey PD
Schizophr Res; 2015 Aug; 166(1-3):110-4. PubMed ID: 26044113
[TBL] [Abstract][Full Text] [Related]
11. The effects of illness severity, cognition, and estimated antipsychotic dopamine receptor occupancy on insight into the illness in schizophrenia: An analysis of clinical antipsychotic trials of intervention effectiveness (CATIE) data.
Ozzoude M; Nakajima S; Plitman E; Chung JK; Kim J; Iwata Y; Caravaggio F; Takeuchi H; Uchida H; Graff-Guerrero A; Gerretsen P
Prog Neuropsychopharmacol Biol Psychiatry; 2019 Mar; 89():207-213. PubMed ID: 30172739
[TBL] [Abstract][Full Text] [Related]
12. The Validity and Sensitivity of PANSS-6 in the Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) Study.
Østergaard SD; Foldager L; Mors O; Bech P; Correll CU
Schizophr Bull; 2018 Feb; 44(2):453-462. PubMed ID: 28575321
[TBL] [Abstract][Full Text] [Related]
13. The relationship between quality of life and clinical efficacy from a randomized trial comparing olanzapine and ziprasidone.
Phillips GA; Van Brunt DL; Roychowdhury SM; Xu W; Naber D
J Clin Psychiatry; 2006 Sep; 67(9):1397-403. PubMed ID: 17017826
[TBL] [Abstract][Full Text] [Related]
14. Initial severity of schizophrenia and efficacy of antipsychotics: participant-level meta-analysis of 6 placebo-controlled studies.
Furukawa TA; Levine SZ; Tanaka S; Goldberg Y; Samara M; Davis JM; Cipriani A; Leucht S
JAMA Psychiatry; 2015 Jan; 72(1):14-21. PubMed ID: 25372935
[TBL] [Abstract][Full Text] [Related]
15. The Clinical Antipsychotic Trials Of Intervention Effectiveness (CATIE) Schizophrenia Trial: clinical comparison of subgroups with and without the metabolic syndrome.
Meyer JM; Nasrallah HA; McEvoy JP; Goff DC; Davis SM; Chakos M; Patel JK; Keefe RS; Stroup TS; Lieberman JA
Schizophr Res; 2005 Dec; 80(1):9-18. PubMed ID: 16125372
[TBL] [Abstract][Full Text] [Related]
16. [Quality of life in patients with schizophrenia: a study of 100 cases].
Zouari L; Thabet JB; Elloumi Z; Elleuch M; Zouari N; Maâlej M
Encephale; 2012 Apr; 38(2):111-7. PubMed ID: 22516268
[TBL] [Abstract][Full Text] [Related]
17. Effects of antipsychotics on insight in schizophrenia: results from independent samples of first-episode and acutely relapsed patients.
Misiak B; Frydecka D; Beszłej JA; Moustafa AA; Tybura P; Kucharska-Mazur J; Samochowiec A; Bieńkowski P; Samochowiec J
Int Clin Psychopharmacol; 2016 Jul; 31(4):185-91. PubMed ID: 26836264
[TBL] [Abstract][Full Text] [Related]
18. [Relationship between insight and self-reported quality of life among shizophrenic patients].
Aghababian V; Auquier P; Baumstarck-Barrau K; Lançon C
Encephale; 2011 Jun; 37(3):162-71. PubMed ID: 21703431
[TBL] [Abstract][Full Text] [Related]
19. Extrapolation between measures of symptom severity and change: an examination of the PANSS and CGI.
Levine SZ; Rabinowitz J; Engel R; Etschel E; Leucht S
Schizophr Res; 2008 Jan; 98(1-3):318-22. PubMed ID: 17949948
[TBL] [Abstract][Full Text] [Related]
20. Efficacy and Safety of MIN-101: A 12-Week Randomized, Double-Blind, Placebo-Controlled Trial of a New Drug in Development for the Treatment of Negative Symptoms in Schizophrenia.
Davidson M; Saoud J; Staner C; Noel N; Luthringer E; Werner S; Reilly J; Schaffhauser JY; Rabinowitz J; Weiser M; Luthringer R
Am J Psychiatry; 2017 Dec; 174(12):1195-1202. PubMed ID: 28750582
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
